Pulmonary hypertension: screening and evaluation in scleroderma

@article{York2011PulmonaryHS,
  title={Pulmonary hypertension: screening and evaluation in scleroderma},
  author={Michael R York and Harrison W. Farber},
  journal={Current Opinion in Rheumatology},
  year={2011},
  volume={23},
  pages={536–544}
}
  • M. York, H. Farber
  • Published 1 November 2011
  • Medicine
  • Current Opinion in Rheumatology
Purpose of reviewThe review provides an update of the epidemiology, pathogenesis, risk factors, screening and treatment of pulmonary arterial hypertension in systemic sclerosis. Recent findingsSeveral recent studies have investigated the utility of several noninvasive screening methods and the propagation of new treatments promise the clinician better outcomes than the current median survival time of 1 year for patients with scleroderma-related pulmonary arterial hypertension. SummaryPulmonary… Expand
Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment
Peter J. Engel, MD The Christ Hospital Cincinnati, OH Sarcoidosis-associated pulmonary hypertension (SAPH) has been reported in 10% of all sarcoidosis patients. In the United States, the prevalenceExpand
Advances in predicting patient survival in pulmonary sarcoidosis
ABSTRACT Introduction: Pulmonary disease remains the most common reason for death in sarcoidosis with pulmonary fibrosis and pulmonary hypertension the two most common causes of mortality. AlthoughExpand
Pulmonary arterial hypertension in SLE: what do we know?
TLDR
As the symptoms of PH in SLE can be mild and non-specific in early stages, an increasing awareness of this devastating complication is essential for early diagnosis, and prompt treatment with newer PAH therapy as well as immunosuppression can reduce morbidity and prolong survival. Expand
Systemic sclerosis-associated pulmonary arterial hypertension.
TLDR
An up-to-date, focused review of SSc-PAH and how it differs from IPAH, including pathogenesis, appropriate screening for disease onset, and new approaches to treatment and longitudinal assessment of this disease are provided. Expand
Prognostic factors in pulmonary arterial hypertension: Literature review.
TLDR
This article centered on the prognosis factor in pulmonary arterial hypertension, a continuation of ESC guidelines, which is used to determine the length of patients' life expectancy. Expand
Clinical outcome and survival in 30 pulmonary hypertension patients with high severity indices and advanced functional class
TLDR
These patients with pulmonary hypertension patients with NYHA functional class III and above with worsening severity indicators who were labeled as a high-risk group showed continuous deterioration in their clinical status despite escalation of therapy with current guidelines are recommended for early lung transplantation. Expand
Pulmonary hypertension in patients with interstitial lung disease.
TLDR
A brief overview of biomarkers indicative of vascular remodeling in interstitial lung disease is provided, the current state of knowledge regarding patients with PH and ILD is summarized and future perspectives that remain to be addressed are highlighted. Expand
Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
TLDR
R rigorous phenotyping and search for novel therapies are desperately needed for this devastating condition. Expand
Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort
TLDR
This study is the first to identify a high frequency of LHD in early PH correlating with normal NT-proBNP levels but increased MR-proANP and MR- proADM levels in SSc patients. Expand
Premature atherosclerosis in systemic sclerosis patients: Its relation to disease parameters and to traditional risk factors
TLDR
The findings confirm the presence of premature atherosclerosis in SSc patients assessed by significant impairment of FMD, flow change and ccIMT, and it is associated with traditional cardiovascular risk factors such as age, dyslipidemia and obesity (BMI) as well as with the use of steroids and markers of inflammation such as CRP and ESR. Expand
...
1
2
...

References

SHOWING 1-10 OF 53 REFERENCES
Screening for pulmonary arterial hypertension in systemic sclerosis
TLDR
Current practice favours annual screening of all SSc patients using Doppler echocardiography to detect elevated right heart pressures, but further research is needed to identify the optimal tools and the screening approach with greatest specificity and selectivity. Expand
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
TLDR
The prevalence of systemic sclerosis associated pulmonary arterial hypertension in this cohort was similar to that of other catheter based studies and lower than that of previous echo based studies. Expand
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.
TLDR
The prevalence of PHT in SSc is high and the detection of P HT at any time in the disease course is associated with substantial mortality, demonstrating the value of echocardiographic screening in all patients with SSC. Expand
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.
TLDR
There are significant clinical and survival differences between IPAH and PAH-Scl, and the presence of left heart disease, although more common in PAH, was not predictive of the higher mortality in these patients. Expand
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
TLDR
While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD-associated PH is particularly grim and survival in SSc complicated by PH remains poor despite currently available treatment options. Expand
Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies
TLDR
The observations support use of RHC to confirm the presence of precapillary PH suspected by noninvasive testing and identified patients at high risk who should be carefully monitored. Expand
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
TLDR
This retrospective analysis of consecutive SSc patients from 2 large referral centers who had PH-ILD confirmed by right-sided heart catheterization and who received targeted PAH therapies concluded that there were no clear benefits from these therapies and Deterioration in oxygenation was an important determinant of long-term survival. Expand
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
TLDR
The high incidence of postcapillary PH highlights the value of RHC in investigating suspected PAH and the estimated incidence of PAH among patients with SSc was 0.61 cases per 100 patient-years. Expand
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
TLDR
A decreasing DLCO is an excellent predictor of the subsequent development of isolated PHT in limited scleroderma, and newer agents that are more effective in treating PHT may also be helpful in altering the natural history of this serious complication inlimited sclerodma. Expand
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.
TLDR
This screening algorithm, based on dyspnea, Doppler echocardiographic evaluation of VTR, and RHC, enabled early detection of PAH at a mild stage and whether this early diagnosis translates into improved prognosis for patients with mild PAH will be evaluated in the ongoing 3-year followup. Expand
...
1
2
3
4
5
...